Retinal Vein Occlusion Treatment Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Retinal Vein Occlusion Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type (Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO)), By Treatment (Anti-vascular Endothelial Growth Factor (Anti-VEGF), Corticosteroid Drugs, Others), By End-user (Hospital & Clinics, Retail Pharmacy, Others) By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Retinal Vein Occlusion (RVO) Treatment Market is projected to experience robust growth, escalating from USD 3.13 billion in 2025 to USD 4.68 billion by 2031, at a compound annual growth rate of 6.93%. This market primarily encompasses pharmacotherapies, notably anti-vascular endothelial growth factor (anti-VEGF) agents and corticosteroid implants, designed to mitigate macular edema and enhance visual acuity in patients afflicted by thrombotic retinal blockages. The market's expansion is fundamentally propelled by a globally aging population and the increasing prevalence of lifestyle-related risk factors such as hypertension, diabetes mellitus, and cardiovascular disorders, all of which significantly elevate the incidence of retinal vascular events. These systemic health issues compromise retinal vascular integrity, thereby increasing the patient pool susceptible to such events and consequently driving demand for effective pharmacotherapies to manage vision-threatening complications; this is evident in the strong financial performance of leading therapeutics like Eylea HD, which saw significant sales increases following its RVO approval. Additionally, the widespread adoption of advanced anti-VEGF and corticosteroid therapeutics, coupled with a robust pipeline of novel biosimilars, is reshaping market dynamics by addressing the critical need for reduced treatment burden through extended durability, which minimizes the frequency of invasive intravitreal injections and improves long-term compliance, as demonstrated by the rapid uptake of high-strength formulations and the aggressive expansion of innovative retinal therapies such as Vabysmo.
Market Driver
The escalating prevalence of lifestyle-related comorbidities, particularly diabetes and hypertension, alongside an expanding global geriatric population, stands as a primary catalyst for the retinal vein occlusion treatment market. These systemic health issues significantly compromise retinal vascular integrity, leading to a higher incidence of thrombotic events that necessitate therapeutic intervention. As the patient pool susceptible to these vascular disorders grows, there is a consequential rise in the demand for effective pharmacotherapies to manage vision-threatening complications like macular edema. This surge in clinical demand is reflected in the financial performance of leading therapeutics; according to Regeneron Pharmaceuticals, October 2025, in the 'Third Quarter 2025 Financial and Operating Results', U.S. net sales of Eylea HD increased 10% to $431 million, driven by higher sales volumes and rising demand following its approval for retinal vein occlusion. Simultaneously, the widespread adoption of advanced anti-VEGF and corticosteroid therapeutics, coupled with a robust pipeline of novel biosimilars, is reshaping market dynamics by addressing the critical need for reduced treatment burden. Clinicians and patients are increasingly prioritizing next-generation agents that offer extended durability, thereby reducing the frequency of invasive intravitreal injections and improving long-term compliance. This transition toward higher-efficacy treatments is evident in product uptake data; according to Bayer, November 2025, in the 'Third Quarter 2025 Financial Report', the new high-strength formulation of aflibercept has rapidly gained traction, now accounting for more than a quarter of the product’s total sales mix. This competitive shift is further underscored by the broader market momentum, where according to Roche, July 2025, sales of the bispecific antibody Vabysmo surged 18% to CHF 2.1 billion in the first half of the year, highlighting the aggressive expansion of the innovative retinal therapy segment.
Market Challenge
However, the market's growth faces a significant impediment due to the substantial treatment burden inherent in chronic anti-VEGF therapy. While these pharmacotherapies offer functional improvements, the necessity for frequent intravitreal injections creates considerable logistical and psychological strain on patients, leading to injection fatigue, non-compliance, and, ultimately, treatment discontinuation. This rigorous regimen, often requiring monthly or bimonthly clinical visits, disrupts daily life and incurs significant indirect costs for caregivers, effectively acting as a ceiling on market volume and eroding potential revenue. The severity of this attrition is highlighted by reports that 63% of surveyed specialists experienced patient loss to follow-up in 2025 due to treatment access and burden challenges. Such high rates of drop-out demonstrate how non-compliance, driven by the demanding nature of current delivery methods, directly erodes the addressable market size.
Market Trends
In response, the Global RVO Treatment Market is undergoing a pivotal transformation marked by a shift toward extended-duration anti-VEGF dosing regimens, focusing on developing novel antibody biopolymer conjugates designed to maintain therapeutic intraocular concentrations for much longer periods, thereby enabling biannual dosing without compromising visual gains, as exemplified by positive data from studies on agents like tarcocimab tedromer. Concurrently, the market penetration of cost-effective anti-VEGF biosimilars is fundamentally reshaping the economic landscape of retinal care by dismantling the pricing monopoly of branded biologics. As patents for legacy anti-VEGF agents expire, healthcare systems are aggressively integrating interchangeable biosimilars to manage escalating costs, with strong commercial volume reflecting a robust acceptance of these fiscally sustainable and clinically equivalent alternatives in practice.
Key Market Players
* AbbVie Inc.
* F. Hoffmann-La Roche Ltd.
* Regeneron Pharmaceuticals Inc.
* Taiwan Liposome Company, Ltd.
* Aerie Pharmaceuticals Inc.
* CalciMedica Inc.
* Outlook Therapeutics, Inc.
* Kodiak Sciences Inc.
* Chugai Pharmaceutical Co., Ltd.
* Pfizer Inc.
Report Scope
In this report, the Global Retinal Vein Occlusion Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Retinal Vein Occlusion Treatment Market, By Disease Type
* Central Retinal Vein Occlusion (CRVO)
* Branch Retinal Vein Occlusion (BRVO)
# Retinal Vein Occlusion Treatment Market, By Treatment
* Anti-vascular Endothelial Growth Factor (Anti-VEGF)
* Corticosteroid Drugs
* Others
# Retinal Vein Occlusion Treatment Market, By End-user
* Hospital & Clinics
* Retail Pharmacy
* Others
# Retinal Vein Occlusion Treatment Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Retinal Vein Occlusion Treatment Market.
Available Customizations:
Global Retinal Vein Occlusion Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Retinal Vein Occlusion Treatment Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Disease Type (Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO))
5.2.2. By Treatment (Anti-vascular Endothelial Growth Factor (Anti-VEGF), Corticosteroid Drugs, Others)
5.2.3. By End-user (Hospital & Clinics, Retail Pharmacy, Others)
5.2.4. By Region
5.2.5. By Company (2025)
5.3. Market Map
6. North America Retinal Vein Occlusion Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Disease Type
6.2.2. By Treatment
6.2.3. By End-user
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Retinal Vein Occlusion Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Disease Type
6.3.1.2.2. By Treatment
6.3.1.2.3. By End-user
6.3.2. Canada Retinal Vein Occlusion Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Disease Type
6.3.2.2.2. By Treatment
6.3.2.2.3. By End-user
6.3.3. Mexico Retinal Vein Occlusion Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Disease Type
6.3.3.2.2. By Treatment
6.3.3.2.3. By End-user
7. Europe Retinal Vein Occlusion Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Disease Type
7.2.2. By Treatment
7.2.3. By End-user
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Retinal Vein Occlusion Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Disease Type
7.3.1.2.2. By Treatment
7.3.1.2.3. By End-user
7.3.2. France Retinal Vein Occlusion Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Disease Type
7.3.2.2.2. By Treatment
7.3.2.2.3. By End-user
7.3.3. United Kingdom Retinal Vein Occlusion Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Disease Type
7.3.3.2.2. By Treatment
7.3.3.2.3. By End-user
7.3.4. Italy Retinal Vein Occlusion Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Disease Type
7.3.4.2.2. By Treatment
7.3.4.2.3. By End-user
7.3.5. Spain Retinal Vein Occlusion Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Disease Type
7.3.5.2.2. By Treatment
7.3.5.2.3. By End-user
8. Asia Pacific Retinal Vein Occlusion Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Disease Type
8.2.2. By Treatment
8.2.3. By End-user
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Retinal Vein Occlusion Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Disease Type
8.3.1.2.2. By Treatment
8.3.1.2.3. By End-user
8.3.2. India Retinal Vein Occlusion Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Disease Type
8.3.2.2.2. By Treatment
8.3.2.2.3. By End-user
8.3.3. Japan Retinal Vein Occlusion Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Disease Type
8.3.3.2.2. By Treatment
8.3.3.2.3. By End-user
8.3.4. South Korea Retinal Vein Occlusion Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Disease Type
8.3.4.2.2. By Treatment
8.3.4.2.3. By End-user
8.3.5. Australia Retinal Vein Occlusion Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Disease Type
8.3.5.2.2. By Treatment
8.3.5.2.3. By End-user
9. Middle East & Africa Retinal Vein Occlusion Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Disease Type
9.2.2. By Treatment
9.2.3. By End-user
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Retinal Vein Occlusion Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Disease Type
9.3.1.2.2. By Treatment
9.3.1.2.3. By End-user
9.3.2. UAE Retinal Vein Occlusion Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Disease Type
9.3.2.2.2. By Treatment
9.3.2.2.3. By End-user
9.3.3. South Africa Retinal Vein Occlusion Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Disease Type
9.3.3.2.2. By Treatment
9.3.3.2.3. By End-user
10. South America Retinal Vein Occlusion Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Disease Type
10.2.2. By Treatment
10.2.3. By End-user
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Retinal Vein Occlusion Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Disease Type
10.3.1.2.2. By Treatment
10.3.1.2.3. By End-user
10.3.2. Colombia Retinal Vein Occlusion Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Disease Type
10.3.2.2.2. By Treatment
10.3.2.2.3. By End-user
10.3.3. Argentina Retinal Vein Occlusion Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Disease Type
10.3.3.2.2. By Treatment
10.3.3.2.3. By End-user
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Retinal Vein Occlusion Treatment Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. AbbVie Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. F. Hoffmann-La Roche Ltd.
15.3. Regeneron Pharmaceuticals Inc.
15.4. Taiwan Liposome Company, Ltd.
15.5. Aerie Pharmaceuticals Inc.
15.6. CalciMedica Inc.
15.7. Outlook Therapeutics, Inc.
15.8. Kodiak Sciences Inc.
15.9. Chugai Pharmaceutical Co., Ltd.
15.10. Pfizer Inc.
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們